Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. 1998

A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
Departments of Pediatrics, Ophthalmology, and Pharmacology, University of Montreal, Canada.

OBJECTIVE We studied the ontogeny of the expression of cyclooxygenase-1 and cyclooxygenase-2 in the ductus arteriosus and evaluated their functional significance. METHODS The expression of cyclooxygenase-1 and cyclooxygenase-2 was studied in ductus arteriosus of fetal (at approximately 75% gestation) and term newborn pig. Effects of selective inhibitors of cyclooxygenase-1 and cyclooxygenase-2 on ductal patency were evaluated by Doppler ultrasonography. RESULTS Ductus arteriosus of the fetus expressed virtually only cyclooxygenase-1 immunoreactive protein and activity. In contrast, the ductus of the term newborn pig (<45 minutes old) contained proteins of both cyclooxygenase-1 and cyclooxygenase-2, but the latter contributed to >90% of prostaglandin E2 formation. The selective cyclooxygenase-2 inhibitor DuP697 reduced prostaglandin E2 levels in the ductus arteriosus, albeit not in plasma, but did not affect ductal patency in the newborn pig (<1(1/2) hours old); in contrast, the cyclooxygenase-1 inhibitor valeryl salicylate, like indomethacin, markedly reduced levels of prostaglandin E2 in the plasma and ductus arteriosus and caused significant constriction of the ductus arteriosus. CONCLUSIONS The ductus arteriosus of the term newborn pig, in contrast to that of the fetus, expresses cyclooxygenase-2, but circulating prostaglandins, arising mostly from cyclooxygenase-1, seem to exert the major control on ductal patency in vivo. Our data suggest that cyclooxygenase-2 inhibitors might be better alternatives for the fetus than nonselective cyclooxygenase blockers if indicated for maternal conditions such as inflammation or for tocolysis.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D011451 Prostaglandin-Endoperoxide Synthases Enzyme complexes that catalyze the formation of PROSTAGLANDINS from the appropriate unsaturated FATTY ACIDS, molecular OXYGEN, and a reduced acceptor. Fatty Acid Cyclo-Oxygenase,PGH Synthase,Prostaglandin H Synthase,Prostaglandin Synthase,Prostaglandin-Endoperoxide Synthase,Arachidonic Acid Cyclooxygenase,Cyclo-Oxygenase,Cyclooxygenase,Cyclooxygenases,Hydroperoxide Cyclase,PGH2 Synthetase,Prostaglandin Cyclo-Oxygenase,Prostaglandin Cyclooxygenase,Prostaglandin Endoperoxide Synthetase,Prostaglandin G-H Synthase,Prostaglandin H2 Synthetase,Prostaglandin Synthetase,Cyclase, Hydroperoxide,Cyclo Oxygenase,Cyclo-Oxygenase, Fatty Acid,Cyclo-Oxygenase, Prostaglandin,Cyclooxygenase, Arachidonic Acid,Cyclooxygenase, Prostaglandin,Endoperoxide Synthetase, Prostaglandin,Fatty Acid Cyclo Oxygenase,G-H Synthase, Prostaglandin,Prostaglandin Cyclo Oxygenase,Prostaglandin Endoperoxide Synthases,Prostaglandin G H Synthase,Synthase, PGH,Synthase, Prostaglandin,Synthase, Prostaglandin G-H,Synthase, Prostaglandin H,Synthase, Prostaglandin-Endoperoxide,Synthases, Prostaglandin-Endoperoxide,Synthetase, PGH2,Synthetase, Prostaglandin,Synthetase, Prostaglandin Endoperoxide,Synthetase, Prostaglandin H2
D004373 Ductus Arteriosus A fetal blood vessel connecting the pulmonary artery with the descending aorta. Arteriosus, Ductus
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005333 Fetus The unborn young of a viviparous mammal, in the postembryonic period, after the major structures have been outlined. In humans, the unborn young from the end of the eighth week after CONCEPTION until BIRTH, as distinguished from the earlier EMBRYO, MAMMALIAN. Fetal Structures,Fetal Tissue,Fetuses,Mummified Fetus,Retained Fetus,Fetal Structure,Fetal Tissues,Fetus, Mummified,Fetus, Retained,Structure, Fetal,Structures, Fetal,Tissue, Fetal,Tissues, Fetal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000831 Animals, Newborn Refers to animals in the period of time just after birth. Animals, Neonatal,Animal, Neonatal,Animal, Newborn,Neonatal Animal,Neonatal Animals,Newborn Animal,Newborn Animals
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D015232 Dinoprostone The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. PGE2,PGE2alpha,Prostaglandin E2,Prostaglandin E2alpha,PGE2 alpha,Prepidil Gel,Prostaglandin E2 alpha,Prostenon,E2 alpha, Prostaglandin,E2, Prostaglandin,E2alpha, Prostaglandin,Gel, Prepidil,alpha, PGE2,alpha, Prostaglandin E2
D051545 Cyclooxygenase 1 A constitutively-expressed subtype of prostaglandin-endoperoxide synthase. It plays an important role in many cellular processes. Prostaglandin H Synthase-1,COX-1 Prostaglandin Synthase,Cyclo-Oxygenase I,Cyclooxygenase-1,COX 1 Prostaglandin Synthase,Cyclo Oxygenase I,Prostaglandin H Synthase 1,Prostaglandin Synthase, COX-1,Synthase, COX-1 Prostaglandin

Related Publications

A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
May 2001, American journal of physiology. Heart and circulatory physiology,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
November 1998, Anesthesia and analgesia,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
September 2006, Pediatric research,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
January 1970, Investigative radiology,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
December 1968, La Presse medicale,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
July 1994, Archives of disease in childhood. Fetal and neonatal edition,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
November 1993, Archives of disease in childhood,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
May 1994, Archives of disease in childhood. Fetal and neonatal edition,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
January 1972, Annales de medecine interne,
A M Guerguerian, and P Hardy, and M Bhattacharya, and P Olley, and R I Clyman, and J C Fouron, and S Chemtob
July 2022, International heart journal,
Copied contents to your clipboard!